Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000392635

Medchemexpress LLC JMJD1C-IN-1 | 861224-48-8 | 99.99% | 317.36 | 25 MG
SDP

Catalog No. 5000392635
Encompass_Preferred

JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). It inhibits the binding of JMJD1C to H3K9me2 peptide substrate and disrupts intratumoral regulatory T (Treg) cell fitness by promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. It demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models and can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells.

  • Orally active and selective inhibitor of JMJD1C.
  • Disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms.
  • Demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models.
  • Can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells.

Catalog No. 50-003-92635 Supplier Medchemexpress LLC Supplier No. 25MGHY162275
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). It inhibits the binding of JMJD1C to H3K9me2 peptide substrate and disrupts intratumoral regulatory T (Treg) cell fitness by promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. It demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models and can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells.

  • Orally active and selective inhibitor of JMJD1C.
  • Disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms.
  • Demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models.
  • Can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.